Literature DB >> 2802417

Iatrogenic immunization with bovine thrombin: a mechanism for prolonged thrombin times after surgery.

M J Flaherty1, R Henderson, M H Wener.   

Abstract

Unexplained very-prolonged thrombin times (greater than 300 s) were found in plasma from four patients. Other coagulation variables were normal, and there was no history of coagulopathy. Mixing studies suggested the presence of thrombin inhibitors in patient plasma. Substitution of human thrombin for bovine thrombin in performing the thrombin time test resulted in normal clotting times, indicating that the inhibitory activity was directed primarily against bovine thrombin. Each patient had been treated with topical bovine thrombin during previous surgery. In the one patient with a preoperative thrombin time, the initial value was normal and prolongation began 16 days after surgery. An enzyme-linked immunoassay showed elevated levels of IgM or IgG antibodies to bovine thrombin in each patient tested. Affinity-purified antibodies to bovine thrombin from patient serum prolonged the thrombin time of normal plasma. These results suggest that iatrogenic immunization by intraoperative exposure to bovine thrombin is responsible for antibodies to bovine thrombin, which accounts for the prolonged thrombin times found in some patients after surgery.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2802417     DOI: 10.7326/0003-4819-111-8-631

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  8 in total

1.  Immunological consequences of topical bovine thrombin.

Authors:  J L Zehnder; L L Leung
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

2.  Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose.

Authors:  J G Schoenecker; R K Hauck; M C Mercer; W Parker; J H Lawson
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

3.  Exposure of mice to topical bovine thrombin induces systemic autoimmunity.

Authors:  J G Schoenecker; R K Johnson; A P Lesher; J D Day; S D Love; M R Hoffman; T L Ortel; W Parker; J H Lawson
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

4.  Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin.

Authors:  T L Ortel; M C Mercer; E H Thames; K D Moore; J H Lawson
Journal:  Ann Surg       Date:  2001-01       Impact factor: 12.969

5.  Acute in-vivo evaluation of bleeding with Gelfoam plus saline and Gelfoam plus human thrombin using a liver square lesion model in swine.

Authors:  George L Adams; Roberto J Manson; Vic Hasselblad; Linda K Shaw; Jeffrey H Lawson
Journal:  J Thromb Thrombolysis       Date:  2008-07-16       Impact factor: 2.300

6.  Thrombin use in surgery: an evidence-based review of its clinical use.

Authors:  Sung W Ham; Wesley K Lew; Fred A Weaver
Journal:  J Blood Med       Date:  2010-07-22

7.  Building an immune-mediated coagulopathy consensus: early recognition and evaluation to enhance post-surgical patient safety.

Authors:  Paul Ness; Michael Creer; George M Rodgers; Joseph J Naoum; Kenneth Renkens; Stacy A Voils; W Allan Alexander
Journal:  Patient Saf Surg       Date:  2009-05-22

8.  Clinical use of topical thrombin as a surgical hemostat.

Authors:  Wesley K Lew; Fred A Weaver
Journal:  Biologics       Date:  2008-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.